Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 76 results.
LastUpdate Updated on 22/11/2026 [07:36:00]
pdfxls
previousPage Results 25 to 50 of 76 nextPage  

METHODS FOR PREDICTING POST-ACUTE SEQUELAE OF VIRAL INFECTIONS USING INTERFERON STIMULATED GENE PROTEINS

Publication No.:  WO2026226538A1 29/10/2026
Applicant: 
UNIV OF UTAH RESEARCH FOUNDATION [US]
UNIVERSITY OF UTAH RESEARCH FOUNDATION
WO_2026226538_A1

Absstract of: WO2026226538A1

Described herein are systems, methods, and kits for predicting post-acute sequelae of a viral infection in a subject. The disclosed methods may comprise obtaining a biological sample from the subject during an acute phase of the viral infection, measuring a level of at least one interferon stimulated gene protein in the biological sample, and determining a risk of the subject developing post-acute sequelae based on the measured level of the at least one interferon stimulated gene protein. In some embodiments, the viral infection is a SARS-CoV-2 infection. Also described herein are methods for treating or preventing post-acute sequelae of a viral infection in a subject in need thereof.

REPLICATION INCOMPETENT HERPES SIMPLEX VIRUS TYPE 1 VIRAL VACCINE

Publication No.:  US20260335432A1 29/10/2026
Applicant: 
IMMVIRA BIOPHARMACEUTICALS CO LTD [CN]
IMMVIRA BIOPHARMACEUTICALS CO., LIMITED
WO_2024027810_A1

Absstract of: US20260335432A1

Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.

RECOMBINANT mRNA VACCINE AGAINST SARS-COV-2

Publication No.:  WO2026224730A1 29/10/2026
Applicant: 
COUNCIL OF SCIENT & INDUSTRIAL RESEARCH [IN]
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
WO_2026224730_A1

Absstract of: WO2026224730A1

Most of the vaccines developed against SARS-CoV-2 are based on structural proteins of the virus, especially the spike protein. Antibody dependent enhancement of infection is a common hurdle that comes in the way of vaccine development when structural proteins are used. As mutations accumulate a vaccine that might not be showing antibody dependent enhancement might start showing enhancement of infection based on the mutations that emerge. Also, spike protein is heavily prone to mutations thus requiring next generation vaccines based on mutations that might lead to escape from neutralizing antibodies. In our invention we have targeted a non-structural protein (NSP3) for designing a mRNA based vaccine candidate. As this is based on a non-structural protein we do not anticipate antibody dependent enhancement of infection. We used the MacI domain of this protein. We have added a secretory signal to enable secretion of MacI so that all possible immunological pathways are stimulated. Mice based immunizations showed effective IgG production against MacI that also lasted for extended period time post prime boost immunization.

AMPLIFICATION-FREE UNIVERSAL DETECTION METHOD USING CAS12A2 AND MULTIPLE CRRNAS

Publication No.:  WO2026225881A1 29/10/2026
Applicant: 
KOREA RESEARCH INST OF BIOSCIENCE AND BIOTECHNOLOGY [KR]
\uD55C\uAD6D\uC0DD\uBA85\uACF5\uD559\uC5F0\uAD6C\uC6D0
WO_2026225881_A1

Absstract of: WO2026225881A1

The present invention relates to an amplification-free universal detection technique using Cas12a2 and multiple crRNAs. The present invention provides a technique capable of detecting target RNA without separate nucleic acid amplification by utilizing Cas12a2 and multiple crRNAs. In particular, the present invention can universally detect SARS-CoV-2 variants at or below the attomole level with very high specificity and sensitivity. That is, the method according to the present invention has the advantage of being able to maintain consistent diagnostic performance despite the evolution of SARS-CoV-2.

MONOCLONAL ANTIBODIES TO HUMAN NEUROPILIN 1 (NRP1)

Publication No.:  WO2026226718A2 29/10/2026
Applicant: 
THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
WO_2026226718_A2

Absstract of: WO2026226718A2

Monoclonal antibodies and antigen binding fragments thereof are disclosed herein that specifically bind NRP1. Conjugates of these antibodies and antigen binding fragments are also disclosed. Further disclosed are chimeric antigen receptors (CARs) including a disclosed antibody or antigen binding fragment, and cells expressing such chimeric antigen receptors (e.g., CAR T cells), and pharmaceutical compositions including these CAR T cells. Multi-specific antibodies, nucleic acid molecules, vectors including these nucleic acid molecules, and pharmaceutical compositions including these compositions are also provided. Methods are also provided for detecting and/or treating a tumor that express NRP1 in a subject. Methods are further provided for treating a coronavirus infection, such as a SARS-CoV-2 infection, or an Epstein Barr virus (EBV) infection, in a subject.

NON-WOVEN FABRIC CONTAINING A DISINFECTING AGENT AND METHOD FOR PRODUCING THE SAME

Publication No.:  US20260337527A1 29/10/2026
Applicant: 
GLATFELTER GERNSBACH GMBH [DE]
Glatfelter Gernsbach GmbH
EP_3910102_A1

Absstract of: US20260337527A1

The present invention relates to a non-woven fabric, a method for producing a non-woven fabric, a wipe or tissue and uses thereof as well as a disinfecting method, in particular against bacteria and viruses, such as coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The non-woven fabric comprises pulp fibers and/or cellulosic fibers, a binder, a cationic polymer, and a disinfecting agent.

LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOF

Publication No.:  US20260335429A1 29/10/2026
Applicant: 
FREIE UNIV BERLIN [DE]
FREIE UNIVERSIT\u00C4T BERLIN
WO_2024052336_PA

Absstract of: US20260335429A1

It is provided a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2′-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome.

DIGITAL FERROFLUIDIC DEVICE AND METHOD FOR MULTIPLEXED ASSAYS AND VIRAL TESTING

Publication No.:  US20260335895A1 29/10/2026
Applicant: 
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
WO_2024050485_PA

Absstract of: US20260335895A1

A ferrofluidic fluid assay device uses swarm of millimeter-sized magnets was employed as mobile robotic agents (“ferrobots”) for precise and robust handling of magnetized sample droplets and high-fidelity delivery of flexible assay workflows. Within a palm-sized printed circuit board-based programmable platform a myriad of sample handling and bioanalytical operations involved in pooled testing can be performed. This automated technology was applied using the loop-mediated isothermal amplification and detection of SARS-COV-2 virus in clinical samples, where the test results completely matched those obtained off-chip. This technology is easily manufacturable and distributable, and its adoption for viral testing could lead to a 10 to 300-fold reduction in reagent costs, and three orders of magnitude reduction in instrumentation cost. Multiplexed assays may also be performed on a single device.

COMPOUNDS FOR TREATMENT OF INFLAMMATORY PROCESSES

Publication No.:  US20260337187A1 29/10/2026
Applicant: 
THORNE LTD [CA]
THORNE LIMITED
WO_2024061894_PA

Absstract of: US20260337187A1

The present disclosure relates to the use of compounds such as compounds of Formula I or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for example, in pharmaceutical compositions and in the treatment of diseases, disorders or conditions such as diseases, disorders or conditions treatable by inhibiting SWAP-70 and/or treatable by inhibiting neutrophil reactive oxygen species (ROS) production, neutrophil NETosis, B lymphocyte plasmablast development, B lymphocyte IgE production, mast cell degranulation, eosinophil ROS production, mast cell cytokine release, B lymphocyte cytokine release, endothelial cell cytokine release, endothelial cell-immune cell interactions, and/or macrophage/monocyte migration, such as treatment of lung inflammation induced by viruses such as SARS-CoV-2:

COMPOSITIONS AND METHODS OF MINIMIZING LONG COVID

Publication No.:  US20260335274A1 29/10/2026
Applicant: 
AUGUSTA UNIVERSITY RESEARCH INST INC [US]
AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
WO_2024059842_PA

Absstract of: US20260335274A1

Pharmaceutical formulations for nasal administration are disclosed. The pharmaceutical formulation contains a green tea catechin derivative (such as an epigallocatechin-3-gallate-palmitate); and preferably further includes a carbohydrate (such as a polysaccharide); and a pharmaceutically acceptable carrier. The pharmaceutical formulation has a viscosity sufficient to maintain the green tea catechin derivative in contact with nasal epithelial cells optionally for at least about 30 minutes in the presence of mucus. Also described are methods of using the nasal formulations for preventing, reducing, and/or treating neurological damages caused by exposure to a virus, such as a SARS-CoV-2. For example, the disclosed pharmaceutical formulations can treat or prevent one or more symptoms of long COVID in an infected subject, and/or repair the damaged nasal epithelial cells, neuroepithelial cells, vascular cells, and/or neurons and restore their functions in a subject recovered from a COVID infection, such as the olfactory function of these cells.

TLR7/8 ANTAGONISTS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTIONS

Publication No.:  EP4830786A2 28/10/2026
Applicant: 
MERCK HEALTHCARE KGAA [DE]
Merck Healthcare KGaA
EP_4830786_A2

Absstract of: EP4830786A2

0001 The present invention encompasses TLR7/8 antagonists for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

CYSTEAMINE FOR THE TREATMENT OF SARS-COV-2 INFECTION

Publication No.:  ZA202600775B 28/10/2026
Applicant: 
THE REGENTS OF THE UNIV OF MICHIGAN [US]
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
WO_2021231570_A1

Absstract of: ZA202600775B

Provided herein are methods for the treatment and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.

BROADLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND SARS-COV VARIANTS

Publication No.:  EP4828727A2 28/10/2026
Applicant: 
US HEALTH [US]
The United States of America, as represented by the Secretary, Department of Health and Human Services
MX_2026005520_A

Absstract of: MX2026005520A

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.

ANTI-SARS-COV-2-SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

Publication No.:  ZA202102442B 28/10/2026
Applicant: 
REGENERON PHARMACEUTICALS INC [US]
REGENERON PHARMACEUTICALS, INC.
AU_2020340881_A1

Absstract of: ZA202102442B

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections). The present disclosure provides neutralizing human antigen-binding proteins that specifically bind to SARS-CoV-2-S, for example, antibodies or antigen-binding fragments thereof.

INFECTIOUS DISEASE ANTIBODIES AND USES THEREOF

Publication No.:  US20260327293A1 22/10/2026
Applicant: 
MOONSHOT ANTIBODIES LLC [US]
Moonshot Antibodies, LLC
US_20260327293_A1

Absstract of: US20260327293A1

0000 Compositions and methods involving effector cells armed with antiviral antibodies are disclosed herein. Such compositions may also include additional antiviral treatments and may be used, for example, to treat subjects having a viral infection (e.g., SARS-COV-2).

SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS COMPOSITION FOR TREATMENT OR PREVENTION OF NOVEL CORONAVIRUS INFECTION DISEASES

Publication No.:  US20260327238A1 22/10/2026
Applicant: 
ALBIUS SCIENCES BETA PTE LTD
ALBIUS SCIENCES BETA PTE. LTD.
US_20260327238_A1

Absstract of: US20260327238A1

The present invention provides a compound useful for the treatment or prevention of SARS-CoV-2 novel coronavirus infection.The present invention relates to a compound represented by formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof:wherein ring A, R1 and R7, R2 and R4, X and Y, as well as Z are according to the definitions as described in the specification;use thereof for the treatment or prevention of SARS-CoV-2 novel coronavirus infection; and pharmaceutical compositions comprising the same.

HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER

Publication No.:  US20260327279A1 22/10/2026
Applicant: 
THE HEALTHY AGING CO [FR]
UNIV OF SOUTH FLORIDA
THE HEALTHY AGING COMPANY
UNIVERSITY OF SOUTH FLORIDA
US_20260327279_A1

Absstract of: US20260327279A1

0000 A HIP/PAP protein, or a derivative thereof, is provided for the treatment and prevention cognition conditions. In particular the HIP/PAP protein, or a derivative thereof is for the treatment of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s). The HIP/PAP protein, or a derivative thereof is also alleviating cognitive deficit in an individual affected by a disorder selected from Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.

RECOMBINANT MURINE PNEUMONIA VIRUS EXPRESSING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE PROTEIN

Publication No.:  US20260325625A1 22/10/2026
Applicant: 
THE U S A AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES [US]
The U.S.A., as represented by the Secretary, Department of Health and Human Services
US_20260325625_A1

Absstract of: US20260325625A1

0000 Recombinant murine pneumonia viruses (rMPV) expressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and their use as live-attenuated virus vaccines against SARS-CoV-2 are described. The rMPV expressing S protein are safe, immunogenic, and efficacious for protecting a subject against SARS-CoV-2 infection and disease, as demonstrated in a non-human primate model. The rMPV induce a strong systemic and mucosal antibody response against the SARS-CoV-2 S protein. Furthermore, a single dose of the live-attenuated rMPV induced strong protection against SARS-CoV-2 challenge, while two doses were fully protective.

IMMUNOLOGICALLY INACTIVE POLY (ETHYLENE GLYCOL) POLYMER DERIVATIVES AND BIOCONJUGATES THEREOF FOR USE AS ALTERNATIVE IN PEGYLATED THERAPEUTICS, PROCESSES FOR THEIR PREPARATION AND THEIR USE

Publication No.:  US20260325627A1 22/10/2026
Applicant: 
JOHANNES GUTENBERG UNIV MAINZ [US]
JOHANNES GUTENBERG-UNIVERSIT\u00C4T MAINZ
US_20260325627_A1

Absstract of: US20260325627A1

0000 Immunological inactive polyether polymers represented by the following formula I: 0000 0000 wherein at least 3% of the residues R include ethylene oxide side chains, oligo(ethylene oxide) side chains and/or glycerol ether side chains and at least 3% of the residues R are hydrogen and R may also be a C1 to C3-alkyloxymethyl side chain. Further, a process for the preparation of the polymers. Finally, the use of the polymers for the preparation of conjugates, especially bioconjugates and the conjugates themselves as alternative for PEGylated therapeutics. The conjugates may include bioactive compounds and/or lipids. They are especially useful for the preparation of vaccines, lipid particles, especially lipid nanoparticles and may be used for the preparation of vaccines against COVID-19.

METHOD FOR TREATING LONG-COVID INDUCED NEUROLOGIC DISEASES

Publication No.:  US20260325548A1 22/10/2026
Applicant: 
UNIV OF SOUTH FLORIDA [US]
University of South Florida
US_20260325548_A1

Absstract of: US20260325548A1

A method of reducing neuroinflammation, tau accumulation, tau phosphorylation, and/or corticosterone secretion to treat or prevent Alzheimer's disease or related dementias, depression, and/or anxiety in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Glucocorticoid receptor antagonists such as mifepristone and nanodendriplexes comprising RNA interference agents targeting FKBP5, IFI16, or a combination thereof exhibit efficacy in reducing abnormal tau accumulation and neuroinflammation in Cov-2-infected patients to reduce neurological symptoms associated with infection.

COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSE

Publication No.:  WO2026222087A2 22/10/2026
Applicant: 
NOVAVAX INC [US]
NOVAVAX, INC.
WO_2026222087_A2

Absstract of: WO2026222087A2

The invention relates to saponin matrix adjuvants comprising Matrix-A and Matrix-C particles at fixed weight ratios between about 70:30 to 10:90 (Matrix-A:Matrix-C), specifically about 60:40, 59:41, 58:42, 57:43, 56:44, 55:45, 54:46, 53:47, 52:48, 51:49, or 50:50, in contrast to conventional 85:15 Matrix-M adjuvant. Matrix-A and Matrix-C are cage-like particles formed from chromatographically separated Quillaja saponin fractions with cholesterol and phosphatidylcholine. At the disclosed ratios, the compositions unexpectedly enhance lysosomal targeting, lysosomal membrane permeabilization, antigen cross-presentation, and activation of antigen-presenting cells, yielding at least about 30–100% higher frequencies of antigen-specific CD8 T cells producing IFN-γ under comparable dosing conditions. The saponin matrix compositions can be formulated with viral antigens (for example SARS-CoV-2 spike, RSV F0, PIV3, hMPV F) or tumor antigens (including defined tumor-associated antigens and neoantigens) to provide vaccines that induce protective antiviral immunity and therapeutic antitumor responses using manufacturing processes compatible with existing Matrix platforms.

METHODS AND COMPOSITIONS FOR CHRONIC INFLAMMATION USING COLCHICINE

Publication No.:  WO2026220159A1 22/10/2026
Applicant: 
MURRAY AND POOLE ENTPR LTD [GB]
MURRAY AND POOLE ENTERPRISES, LTD.
WO_2026220159_A1

Absstract of: WO2026220159A1

Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.

PLPRO INHIBITORS AND METHODS OF USING THE SAME

Publication No.:  WO2026222182A1 22/10/2026
Applicant: 
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA [US]
THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS [US]
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
WO_2026222182_A1

Absstract of: WO2026222182A1

Disclosed herein is a library of SARS-CoV-2 PLpro inhibitors. The compounds described herein represent potent inhibitors of PLpro with activity translating to live virus assays in mammalian and human host cells. Also provided herein are methods of using the PLpro inhibitors for preventing or treating infections, diseases, and/or symptoms caused by exposure to a coronavirus, such as SARS-CoV-2, SARS-CoV-1, and MERS in a subject in need thereof.

COMPOSITIONS AND METHODS FOR ASSESSING THE SEVERITY OF AND TREATING COVID-19

Publication No.:  US20260328785A1 22/10/2026
Applicant: 
THE JOHNS HOPKINS UNIV [US]
The Johns Hopkins University
US_20260328785_A1

Absstract of: US20260328785A1

0000 The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods for assessing the severity of and treating severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or COVID-19. In particular embodiments, a method for treating COVID-19 in a patient comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.

POINT-OF-CARE ON-CHIP IGRA DEVICE AND METHOD FOR MEASURING SPECIFIC T CELL ACTIVATION

Nº publicación: US20260328766A1 22/10/2026

Applicant:

THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND [US]
The Administrators of the Tulane Educational Fund

US_20260328766_A1

Absstract of: US20260328766A1

Method and device for detecting SARS-CoV-2 specific T-Cell interferon-gamma activation is described. By using a microfluidic chip to allow ELISpot interferon gamma release assays (IGRA) be performed using a small amount of fingerstick whole blood sample, fast results can be provided with minimal amount of blood sample.

traducir